文献速递免疫规划卫生政策与健康促进

早期采用HPV两剂次疫苗接种程序:利用证据支持政策以加速影响

Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact.
PubMed 文献 · Vaccine · 2018-06-07

本文回顾加拿大和墨西哥公共卫生当局早期决定采用两剂次HPV疫苗接种(间隔6个月,计划60个月时追加一剂)并同步研究第三剂是否带来额外获益的经验。该延迟第三剂策略使项目更具成本效益、提高依从性并保留完成三剂系列的机会。越来越多证据表明单剂次即可提供持久保护,资源有限地区可考虑先启动单剂次接种。

要点

  • 加拿大和墨西哥公共卫生当局决定两剂次HPV疫苗接种间隔6个月,计划60个月时追加第三剂。
  • 该延迟第三剂策略使项目更具成本效益、提高依从性并保留完成三剂系列的机会。
  • 越来越多证据表明单剂次HPV疫苗接种即可提供持久保护,但证据仍有限。

核心结论

  • 加拿大和墨西哥公共卫生当局早期采用两剂次HPV疫苗接种程序并同步研究第三剂的额外获益,该策略使项目更具成本效益并提高依从性。
  • 越来越多证据表明单剂次HPV疫苗接种即可提供持久保护,但证据仍有限。
  • 资源有限地区可考虑先启动单剂次接种、必要时日后补第二剂,以加速对宫颈癌等HPV相关疾病的影响。

研究设计与样本

  • 本文为政策经验总结与证据回顾,描述加拿大和墨西哥公共卫生当局的决策过程及HPV疫苗免疫原性与有效性证据。

主要发现

  • HPV疫苗最初基于15-26岁女性三剂次方案的有效性获批,但临床开发早期即认识到年轻女孩两剂次即可获得可比免疫原性。
  • 加拿大和墨西哥公共卫生当局决定两剂次间隔6个月接种并于60个月时计划追加一剂,同时进一步研究第三剂是否带来有意义的额外获益。
  • 越来越多证据表明即使单剂次接种也足以提供针对HPV感染及相关疾病的持久保护,但证据仍有限。

临床怎么用

  • 作者认为,为加速HPV疫苗接种的预防效果,部分辖区尤其是资源有限地区可考虑先启动单剂次接种并在必要时日后补第二剂。
  • 作者认为,该做法将便于疫苗接种实施,并可能允许在较大年龄女孩(或适当时女孩和男孩)中开展更大规模补种。

局限性

  • 单剂次HPV疫苗接种可提供持久保护的证据仍有限。
  • 需持续临床试验和生态学研究以巩固单剂次接种方案现有数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although human papillomavirus (HPV) vaccines were initially licensed based on efficacy after three-dose regimens in women aged 15-26 years, it was recognized early in clinical development that comparable immunogenicity could be obtained after just two doses when administered to younger girls. In both Canada and Mexico, public health authorities made the decision to administer two doses 6 months apart with a planned additional dose at 60 months, while simultaneously doing further study to determine if the third dose would confer meaningful additional benefit. This delayed third dose approach permitted a more cost-effective program with opportunities for improved compliance while minimizing injections and leaving open the opportunity to provide a full three-dose vaccination series. It required close cooperation across many governmental and civil society leadership bodies and real-time access to emerging data on HPV vaccine effectiveness. Although still limited, there is increasing evidence that even one-dose vaccination is sufficient to provide prolonged protection against HPV infection and associated diseases. Ongoing clinical trials and ecological studies are expected to consolidate existing data regarding one dose schedule use. However, to accelerate the preventive effect of HPV vaccination some jurisdictions, in particular those with limited resources may already consider the initiation of a one dose vaccination with the possibility of giving the second dose later in life if judged necessary. Such an approach would facilitate vaccination implementation and might permit larger catch-up vaccination programs in older girls (or as appropriate, girls and boys), thereby accelerating the impact on cervical cancer and other HPV-associated diseases.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gilca V, Salmerón-Castro J, Sauvageau C, et al. Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact. Vaccine. 2018. PMID: 29887322. doi:10.1016/j.vaccine.2018.02.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。